Proteins expressed using CHO cell line

Product Type Therapeutic use Manufacturer Year of approval (FDA)
Vectibix Anti-EGFR mAb Metastatic colorectal cancer Amgen 2006
Myozyme α-glucosidase Pompe disease Genzyme 2006
Aldurazyme Laronidase Mucopolysaccharidosis I Genzyme 2006
Orencia Ig-CTLA4 fusion Rheumatoid arthritis Bristol-Myers Squibb 2005
Naglazyme N-acetylgalactosamine-4-sulfatase Mucopolysaccharidosis VI BioMarin Pharmaceutical 2005
Luveris Luteinizing hormone Infertility Serono 2004
Avastin Anti-VEGF mAb Metastatic colorectal cancer & lung cancer Genentech 2004
Advate Factor VIII (engineered) Hemophilia A Baxter 2003
Xolair Anti-IgE mAb Moderate/severe asthma Genentech 2003
Raptiva Anti-CD11a mAb Chronic psoriasis Genentech 2003
Fabrazyme α-galactosidase Fabry disease Genzyme 2003
Rebif Interferon-β Relapsing multiple sclerosis Serono 2002
Humira Anti-TNFα mAb Rheumatoid arthritis Abbott 2002
Aranesp Erythropoietin (engineered) Anemia Amgen 2001
Campath Anti-CD52 mAb Chronic lymphocytic leukemia Genzyme, Bayer 2001
ReFacto Factor VIII Hemophilia A Wyeth 2000
Tenecteplase Tissue plasminogen activator (engineered) Myocardial infraction Genentech 2000
Herceptin Anti-HER2 mAb Metastatic breast cancer Genentech 1998
Enbrel TNFα receptor fusion Rheumatoid arthritis Amgen, Wyeth 1998
Benefix Factor IX Hemophilia B Wyeth 1997
Follistim/Gonal-F Follicle stimulating hormone Infertility Serono/NV Organon 1997
Rituxan Anti-CD20 mAb Non-Hodgkin’s lymphoma Genentech, Biogen Idec 1997
Avonex Interferon-β Relapsing multiple sclerosis Biogen Idec 1996
Cerezyme β-glucocerebrosidase Gaucher’s disease Genzyme 1994
Pulmozyme Deoxyribonuclease I Cystic fibrosis Genentech 1993
Epogen/Procrit Erythropoietin Anemia Amgen/Ortho Biotech 1989
Activase Tissue plasminogen activator Acute myocardial infraction Genentech 1987

January 21, 2013 at 2:20 pm

Leave a Comment